New therapeutic target in primary headaches - blocking theCGRP receptor

56 Citationer (Scopus)

Abstract

The primary headaches are among the most prevalent neurological disorders, afflicting up to 16% of the adult population. The associated pain originates from intracranial blood vessels that are innervated by sensory nerves storing several neurotransmitters. In primary headaches, there is a clear association between the headache and the release of calcitonin gene-related peptide (CGRP), but not other neuronal messengers. The specific purpose of this review is to describe CGRP in the human cranial circulation and to elucidate a possible role for a specific antagonist in the treatment of primary headaches. Acute treatment with administration of a 5-HT(1B/1D) agonist (triptan) results in alleviation of the headache and normalisation of the CGRP level. The mechanism of action of triptans involves vasoconstriction of intracranial vessels and a presynaptic inhibitory effect of sensory nerves. The central role of CGRP in migraine and cluster headache pathophysiology has led to the search for small-molecule CGRP antagonists, which are predicted to have fewer cardiovascular side effects in comparison to the triptans. The initial pharmacological profile of such a group of compounds has recently been disclosed. These compounds have high selectivity for human CGRP receptors and are reportedly efficacious in the relief of acute attacks of migraine.

OriginalsprogEngelsk
TidsskriftExpert Opinion on Therapeutic Targets
Vol/bind7
Udgave nummer3
Sider (fra-til)377-83
Antal sider7
ISSN1472-8222
DOI
StatusUdgivet - jun. 2003
Udgivet eksterntJa

Fingeraftryk

Dyk ned i forskningsemnerne om 'New therapeutic target in primary headaches - blocking theCGRP receptor'. Sammen danner de et unikt fingeraftryk.

Citationsformater